HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases Nasdaq:HOOK

NEW YORK and VIENNA, Austria, April 21, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), an organization growing a brand new class of immunotherapeutics focusing on infectious illnesses and cancers primarily based on its proprietary arenavirus platform, immediately introduced the publication in The Journal of Infectious Ailments of the Section 1 outcomes of HOOKIPA’s VaxWave^®-based prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101, which is at present in a Section 2 scientific trial.

The paper concludes that HB-101 was properly tolerated and induced CMV-specific poly-functional CD8 T cell and neutralizing antibody responses in almost all topics. The absence of vector-neutralizing antibody responses allowed all CMV antigen-specific immune responses to be elevated in a statistically vital method upon repeated vaccine re-administration, which ought to facilitate further booster vaccinations. Therefore, HOOKIPA’s vaccine candidate holds promise for prevention of clinically vital CMV an infection in transplant recipients and unborn kids.

“The influence of CMV infections, particularly within the discipline of immunosuppressed sufferers, like transplant recipients, is extreme and a prophylactic CMV vaccine could be game-changing,” commented Paul Griffiths, MD DSc FRCPath, Professor of Virology, Institute of Immunity & Transplantation at College School London. “The sector wants a vaccine that induces each cell-mediated and humoral immunity. These Section 1 outcomes from HOOKIPA are very encouraging, so I sit up for seeing the outcomes from the Section 2 trial that’s underway in transplant sufferers.”

Cytomegalovirus, or CMV, is a virus that’s generally transmitted in childhood and early maturity. Roughly 60% of the U.S. inhabitants has been uncovered and is latently contaminated. Worldwide information point out that half the individuals in industrialized nations and as much as 99% of individuals in growing nations, together with China and India, have been contaminated. Infections usually lead to lifelong latent persistence of the virus with few signs, if any. Nonetheless, in unborn kids, when contaminated in utero, CMV an infection can result in vital morbidity and mortality. As well as, in immunosuppressed sufferers, reminiscent of transplant recipients, main CMV an infection or reactivation of CMV causes vital morbidity, mortality and graft rejection.

The publication, “A randomized dose-escalating Section I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine towards human cytomegalovirus,” is out there on-line in The Journal of Infectious Diseases.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a scientific stage biopharmaceutical firm growing a brand new class of immunotherapeutics focusing on infectious illnesses and cancers primarily based on its proprietary arenavirus platform that’s designed to reprogram the physique’s immune system.

HOOKIPA’s proprietary arenavirus-based applied sciences, VaxWave^®, a replication-deficient viral vector, and TheraT^®, a replication-attenuated viral vector, are designed to induce sturdy antigen particular CD8⁺ T cells and pathogen-neutralizing antibodies. Each applied sciences are designed to permit for repeat administration to enhance and refresh immune responses. TheraT^® has the potential to induce CD8⁺ T cell response ranges beforehand not achieved by different immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors goal dendritic cells in vivo to activate the immune system.

HOOKIPA’s VaxWave^®-based prophylactic Cytomegalovirus (CMV) vaccine candidate is at present in a Section 2 scientific trial in CMV-negative sufferers awaiting kidney transplantation from residing CMV-positive donors in addition to CMV-positive sufferers awaiting kidney transplantation from CMV-positive or -negative donors. To develop its infectious illness portfolio, HOOKIPA has entered right into a collaboration and licensing settlement with Gilead Sciences, Inc. to collectively analysis and develop purposeful cures for HIV and continual Hepatitis B infections.

As well as, HOOKIPA is constructing a proprietary immuno-oncology pipeline by focusing on virally mediated most cancers antigens, self-antigens and next-generation antigens. The TheraT^® primarily based lead oncology product candidates, HB-201 and HB-202, are in growth for the remedy of Human Papilloma Virus16-positive cancers. The Section half scientific trial for HB-201 was initiated in December 2019. The HB-202 IND submission is meant for the primary half of 2020.

Discover out extra about HOOKIPA on-line at www.hookipapharma.com.

HOOKIPA Ahead Trying Statements
Sure statements set forth on this press launch represent “forward-looking” statements inside the which means of the Personal Securities Litigation Reform Act of 1995, as amended. Ahead-looking statements might be recognized by phrases reminiscent of “believes,” “expects,” “plans,” “potential,” “would” or comparable expressions and the damaging of these phrases. Such forward-looking statements contain substantial dangers and uncertainties that might trigger HOOKIPA’s analysis and scientific growth packages, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by the forward-looking statements. Such dangers and uncertainties embody, amongst others, the uncertainties inherent within the drug growth course of, together with HOOKIPA’s packages’ early stage of growth, the method of designing and conducting preclinical and scientific trials, the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, HOOKIPA’s capability to efficiently set up, defend and defend its mental property, dangers regarding enterprise interruptions ensuing from the coronavirus (COVID-19) illness outbreak or comparable public well being crises and different issues that might have an effect on the sufficiency of current money to fund operations and HOOKIPA’s capability to attain the milestones below the settlement with Gilead. HOOKIPA undertakes no obligation to replace or revise any forward-looking statements. For an extra description of the dangers and uncertainties that might trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding the enterprise of the corporate on the whole, see HOOKIPA’s annual report on Kind 10-Ok for the complete 12 months ended December 31, 2019 which is on the Safety and Alternate Fee’s web site at www.sec.gov and HOOKIPA’s web site at www.hookipapharma.com.

Buyers and others ought to word that we announce materials monetary data to our traders utilizing our investor relations web site (https://ir.hookipapharma.com/), SEC filings, press releases, public convention calls and webcasts. We use these channels, in addition to social media, to speak with our members and the general public about our firm, our companies and different points. It’s doable that the data we publish on social media may very well be deemed to be materials data. Due to this fact, we encourage traders, the media, and others involved in our firm to assessment the data we publish on the U.S. social media channels listed on our investor relations web site.

For additional data, please contact: